Understanding and Overcoming the Early Adaptive Resistance to EGFR Tyrosine-kinase Inhibitors in Lung Cancer Patients

Launched by UNIVERSITY HOSPITAL, TOULOUSE · Jan 7, 2020

Keywords

ClinConnect Summary

This clinical trial is studying how some patients with advanced lung cancer might become resistant to a specific type of treatment called EGFR tyrosine kinase inhibitors (TKIs). These medications are helpful for patients with certain mutations in the EGFR gene, but often, the cancer can find ways to resist the treatment over time. Researchers are looking into a new condition related to this resistance that could help them understand why some patients stop responding to the treatment. By using advanced techniques and patient samples, they aim to identify changes in the cancer cells that could lead to new ways to overcome this resistance and improve treatment outcomes.

If you have non-small cell lung cancer that cannot be surgically removed and has a specific EGFR mutation, you may be eligible to participate in this trial. Key requirements include being a first-time patient receiving treatment with a drug called Osimertinib, or being in a position to receive it after chemotherapy. Participants will undergo tests and provide samples to help researchers learn more about how to combat drug resistance in lung cancer. This study is currently recruiting patients of all genders between the ages of 65 and 74, and it’s an opportunity to contribute to important research that could benefit future lung cancer treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient with non operable and / or metastatic non-small cell lung cancer documented histologically.
• • Pathological diagnosis of NSCLC carrying an EGFR activating mutation associated with sensitivity to the tyrosine kinase inhibitors (TKI) (exons 18, 19 and 21).
• • Sufficient tissue sample quantity and quality for translational research
• • Naïve TKI-treated EGFR patient who can receive first-line treatment with Osimertinib or second-line after chemotherapy
• Exclusion Criteria:
• • Any patient with an exon 20 EGFR mutation.
• • Any disease or pathology that recommend not to perform blood samples collection
• • Any psychological, family, geographical or social condition that could potentially, according to the investigator's judgment, prevent the collection of informed consent or interfere with compliance with the study protocol
• • Patient with a resistance mutation of EGFR
• • Patient under State Medical Assistance
• • Patient deprived of liberty on administrative or judicial decision, or patient under guardianship, curatorship or safeguard of justice